Cabergoline-induced manic episode: case report.

Area of Science:

• Endocrinology
• Neuropsychiatry
• Pharmacology

Background:

• Cabergoline is a dopamine agonist used for hyperprolactinemia, Parkinson's disease, and antipsychotic-induced prolactin elevation.
• It is characterized by a long duration of action, effectively suppressing prolactin levels.
• While beneficial for dosing, its prolonged half-life may complicate the management of adverse effects like psychosis.

Purpose of the Study:

• To report the first documented case of a manic episode associated with cabergoline use.
• To investigate the potential neuropsychiatric adverse effects of cabergoline, specifically mania.
• To emphasize the importance of considering the risk-benefit ratio when prescribing cabergoline.

Main Methods:

• Case report detailing a patient's experience with cabergoline treatment for hyperprolactinemia.
• Review of existing literature on dopamine agonist-induced psychosis and mania.
• Clinical observation and assessment of adverse events.

Main Results:

• The patient developed a manic episode following cabergoline administration for hyperprolactinemia.
• This represents the first reported instance of dopamine agonist-induced mania in the literature.
• Cabergoline, like other dopaminergic agents, is associated with neuropsychiatric adverse effects.

Conclusions:

• Cabergoline can precipitate manic episodes in susceptible individuals.
• Clinicians should exercise caution and carefully evaluate the risk-benefit profile before prescribing cabergoline.
• Further research may be warranted to understand the mechanisms underlying cabergoline-induced mania.